FibroBiologics Appoints New CMO, Adds Director
Ticker: FBLG · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1958777
| Field | Detail |
|---|---|
| Company | Fibrobiologics, INC. (FBLG) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $75,000, $2.36, $13.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-appointment, personnel
TL;DR
FibroBiologics beefs up leadership with a new CMO and a board director.
AI Summary
FibroBiologics, Inc. announced on January 23, 2025, the appointment of Dr. Jonathan L. R. Roth as Chief Medical Officer and the election of Dr. David M. Epstein to its Board of Directors. The company also disclosed compensatory arrangements for these key individuals. This filing follows a period of significant corporate activity for the company.
Why It Matters
The appointment of a new Chief Medical Officer and a new Board member suggests strategic shifts and potential growth initiatives for FibroBiologics in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate strategic shifts, which may carry inherent risks and opportunities for the company.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- Dr. Jonathan L. R. Roth (person) — Appointed Chief Medical Officer
- Dr. David M. Epstein (person) — Elected to Board of Directors
- January 23, 2025 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer for FibroBiologics, Inc.?
Dr. Jonathan L. R. Roth has been appointed as the new Chief Medical Officer for FibroBiologics, Inc.
Who has been elected to the Board of Directors of FibroBiologics, Inc.?
Dr. David M. Epstein has been elected to the Board of Directors of FibroBiologics, Inc.
What is the exact date of this Form 8-K filing?
The date of the report is January 23, 2025.
What is the principal business address of FibroBiologics, Inc.?
The principal business address is 455 E. Medical Center Blvd. Suite 300, Houston, Texas 77598.
What is the SIC code for FibroBiologics, Inc.?
The Standard Industrial Classification code for FibroBiologics, Inc. is 2834 (Pharmaceutical Preparations).
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2025-01-24 16:05:18
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Marke
- $75,000 — and the Board also approved a bonus of $75,000 for Mr. Robert E. Hoffman, the Company'
- $2.36 — ions granted on December 27, 2024 are a $2.36 stock and exercise price, time to matur
- $13.00 — ed to Mr. Garcia on March 1, 2024 are a $13.00 stock and exercise price, time to matur
Filing Documents
- form8-k.htm (8-K) — 58KB
- 0001493152-25-003571.txt ( ) — 233KB
- fblg-20250123.xsd (EX-101.SCH) — 3KB
- fblg-20250123_lab.xml (EX-101.LAB) — 33KB
- fblg-20250123_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: January 24, 2025 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer